57868F 2016 IDMPS Unmet Needs Full size infographic … · HbA1c uncontrolled (≥7%) vs....

1
These data from Wave 1 of the IDMPS show that more needs to be done to monitor whether people are achieving their HbA1c levels and to screen for complications 1 These data from Wave 2 of the IDMPS demonstrate that besides its emotional cost, diabetes also has an economic cost 2 Expected annual hospitalization rates were up to ~5 times greater in those with complications or poor control Hospitalization The expected rate of inpatient days was up to ~16 times greater in those with complications or poor control Inpatient days The expected rate of emergency room visits was up to ~3 times greater in those with complications or poor control Emergency room visits Absenteeism was up to ~9 times greater in those with complications or poor control Absenteeism Middle East /Africa Asia Latin America (N=6,090) (N=4,248) (N=4,678) Microvascular vs. no microvascular 2.37 (1.61, 3.50) 2.58 (1.64, 4.06) 2.87 (1.71, 4.84) Macrovascular vs. no macrovascular 4.35 (2.75, 6.87) 4.68 (2.82, 7.80) 5.38 (2.96, 9.78) HbA1c uncontrolled (≥7%) vs. controlled (<7%) 4.59 (2.96, 7.13) 3.20 (2.02, 5.09) 3.06 (1.74, 5.39) Middle East /Africa Asia Latin America (N=6,090) (N=4,248) (N=4,678) Microvascular vs. no microvascular 2.99 (1.74, 5.14) 2.94 (1.73, 4.99) NS Macrovascular vs. no macrovascular 7.90 (3.95, 15.80) 5.54 (2.81, 10.95) 16.09 (6.84, 37.84) HbA1c uncontrolled (≥7%) vs. controlled (<7%) 11.50 (6.19, 21.34) NS 2.74 (1.27, 5.93) Middle East /Africa Asia Latin America (N=6,090) (N=4,248) (N=4,678) Microvascular vs. no microvascular 2.62 (1.65, 4.17) 2.36 (1.22, 4.54) 3.63 (2.17, 6.06) Macrovascular vs. no macrovascular 3.80 (2.29, 6.31) 3.68 (1.79, 7.55) 3.98 (2.13, 7.44) HbA1c uncontrolled (≥7%) vs. controlled (<7%) NS NS 3.19 (1.84, 5.54) Middle East /Africa Asia Latin America (N=6,090) (N=4,248) (N=4,678) Microvascular vs. no microvascular 2.61 (1.26, 5.39) NS 2.72 (1.24, 5.98) Macrovascular vs. no macrovascular 9.91 (3.65, 26.90) 4.08 (1.61, 10.33) 6.07 (2.23, 16.53) HbA1c uncontrolled (≥7%) vs. controlled (<7%) 4.12 (1.87, 9.11) NS NS Data are incidence rate ratio (95% confidence interval) Data are incidence rate ratio (95% confidence interval); NS=no significant increase Data are incidence rate ratio (95% confidence interval); NS=no significant increase Data are incidence rate ratio (95% confidence interval); NS=no significant increase Find out more References: 1. Chan JCN, et al. Diabetes Care 2009;32:227–233 2. Ringborg A, et al. Int J Clin Pract 2009;63:997–1007 People with Type 1 diabetes People with Type 2 diabetes 17.8% 25.8% Neuropathy People with Type 1 diabetes People with Type 2 diabetes 23.2% 36.0% Microalbuminuria People with Type 1 diabetes People with Type 2 diabetes 17.7% 23.6% Diabetic foot ulcer People with Type 1 diabetes People with Type 2 diabetes 22.4% 35.8% HbA1c People with Type 1 diabetes People with Type 2 diabetes 9.5% 20.5% Retinopathy People with Type 1 diabetes People with Type 2 diabetes 9.2% 10.5% Cholesterol People with Type 1 diabetes: N=1,898 People with Type 2 diabetes: N=9,901 2005 17 countries 937 HCPs 1,898 Type 1 9,901 Type 2 11,799 Wave 1 27 countries 1,538 HCPs 3,507 Type 1 17,232 Type 2 20,739 2006 Wave 2 IDMPS.org The majority of people in the developing world are not achieving diabetes control 1 Did you know: More detailed data from the analysis can be seen below: Macrovascular complications such as stroke and heart failure are associated with high levels of health resource use The greatest risk associated with poorly controlled diabetes was an 11.5 fold increase in expected inpatient days in the Middle East/Africa region Complications or poorly controlled diabetes were associated with an increased rate of missing work People who have never received screening for: People with Type 1 diabetes People with Type 2 diabetes 19.8% 16.6% Cardiovascular disease IDMPS is identifying unmet needs for diabetes in the developing world Many people with diabetes have never received basic screening 1 Complications and poor control in Type 2 diabetes increase health resource use 2 <7% HbA1c of people with Type 2 diabetes have achieved this target 1 of people with Type 1 diabetes have achieved this target 1 25.3% 36.4% Diabetes control is defined as reaching a target of HbA1c <7% 1 Only Only Countries that participated in Wave 1 were Argentina, Bosnia, Bulgaria, China, Colombia, Ecuador, Hong Kong, India, Indonesia, Korea, Malaysia, Romania, Taiwan, Thailand, Tunisia, Turkey, and Venezuela February 2016: SGALB.DIA.15.11.0883a HbA1c, glycated hemoglobin; HCP, healthcare provider

Transcript of 57868F 2016 IDMPS Unmet Needs Full size infographic … · HbA1c uncontrolled (≥7%) vs....

These data from Wave 1 of the IDMPS show that more needs to be done to monitor whether people are achieving their HbA1c levels and to screen for complications1

These data from Wave 2 of the IDMPS demonstrate that besidesits emotional cost, diabetes also has an economic cost2

Expected annual hospitalization rates were up to ~5 times greater in those with complications or poor control

HospitalizationThe expected rate of inpatient days was up to ~16 times greater in those with complications or poor control

Inpatient days

The expected rate of emergency room visits was up to ~3 times greater in those with complications or poor control

Emergency room visitsAbsenteeism was up to ~9 times greater in those with complications or poor control

Absenteeism

Middle East /Africa Asia Latin America (N=6,090) (N=4,248) (N=4,678)

Microvascular vs. no microvascular 2.37 (1.61, 3.50) 2.58 (1.64, 4.06) 2.87 (1.71, 4.84)

Macrovascular vs. no macrovascular 4.35 (2.75, 6.87) 4.68 (2.82, 7.80) 5.38 (2.96, 9.78)

HbA1c uncontrolled (≥7%) vs. controlled (<7%) 4.59 (2.96, 7.13) 3.20 (2.02, 5.09) 3.06 (1.74, 5.39)

Middle East /Africa Asia Latin America (N=6,090) (N=4,248) (N=4,678)

Microvascular vs. no microvascular 2.99 (1.74, 5.14) 2.94 (1.73, 4.99) NS

Macrovascular vs. no macrovascular 7.90 (3.95, 15.80) 5.54 (2.81, 10.95) 16.09 (6.84, 37.84)

HbA1c uncontrolled (≥7%) vs. controlled (<7%) 11.50 (6.19, 21.34) NS 2.74 (1.27, 5.93)

Middle East /Africa Asia Latin America (N=6,090) (N=4,248) (N=4,678)

Microvascular vs. no microvascular 2.62 (1.65, 4.17) 2.36 (1.22, 4.54) 3.63 (2.17, 6.06)

Macrovascular vs. no macrovascular 3.80 (2.29, 6.31) 3.68 (1.79, 7.55) 3.98 (2.13, 7.44)

HbA1c uncontrolled (≥7%) vs. controlled (<7%) NS NS 3.19 (1.84, 5.54)

Middle East /Africa Asia Latin America (N=6,090) (N=4,248) (N=4,678)

Microvascular vs. no microvascular 2.61 (1.26, 5.39) NS 2.72 (1.24, 5.98)

Macrovascular vs. no macrovascular 9.91 (3.65, 26.90) 4.08 (1.61, 10.33) 6.07 (2.23, 16.53)

HbA1c uncontrolled (≥7%) vs. controlled (<7%) 4.12 (1.87, 9.11) NS NS

Data are incidence rate ratio (95% con�dence interval) Data are incidence rate ratio (95% con�dence interval); NS=no signi�cant increase

Data are incidence rate ratio (95% con�dence interval); NS=no signi�cant increase Data are incidence rate ratio (95% con�dence interval); NS=no signi�cant increase

Find out more

References: 1. Chan JCN, et al. Diabetes Care 2009;32:227–233 2. Ringborg A, et al. Int J Clin Pract 2009;63:997–1007

People with Type 1 diabetes

People with Type 2 diabetes

17.8%25.8%

Neuropathy

People with Type 1 diabetes

People with Type 2 diabetes

23.2%36.0%

Microalbuminuria

People with Type 1 diabetes

People with Type 2 diabetes

17.7%23.6%

Diabetic foot ulcer

People with Type 1 diabetes

People with Type 2 diabetes

22.4%35.8%

HbA1c

People with Type 1 diabetes

People with Type 2 diabetes

9.5%20.5%

Retinopathy

People with Type 1 diabetes

People with Type 2 diabetes

9.2%10.5%

Cholesterol

People with Type 1 diabetes: N=1,898 People with Type 2 diabetes: N=9,901

2005

17 countries937 HCPs

1,898 Type 1 9,901 Type 2

11,799Wave 1

27 countries1,538 HCPs

3,507 Type 1 17,232 Type 2

20,7392006Wave 2

IDMPS.org

The majority of people in the developing world are not achieving diabetes control1

Did you know:

More detailed data from the analysis can be seen below:

Macrovascular complications such as stroke and heart failure are associated with high levels of health resource use

The greatest risk associated with poorly controlled diabetes was an 11.5 fold increase in expected inpatient days in the Middle East/Africa region

Complications or poorly controlled diabetes were associated with an increased rate of missing work

People who have never received screening for:

People with Type 1 diabetes

People with Type 2 diabetes

19.8%16.6%

Cardiovascular disease

IDMPS is identifying unmet needs for diabetes in the developing world

Many people with diabetes have never received basic screening1

Complications and poor control in Type 2 diabetes increase health resource use2

<7%HbA1c

of people with Type 2 diabetes have achieved

this target1

of people with Type 1 diabetes have achieved

this target1

25.3% 36.4%

Diabetes control is de�ned as reaching a target of HbA1c <7%1

OnlyOnly

Countries that participated in Wave 1 were Argentina, Bosnia, Bulgaria, China, Colombia, Ecuador, Hong Kong, India, Indonesia, Korea, Malaysia, Romania, Taiwan, Thailand, Tunisia, Turkey, and Venezuela

February 2016: SGALB.DIA.15.11.0883a HbA1c, glycated hemoglobin; HCP, healthcare provider